Issue 37, 2013

DNA display for drug discovery

Abstract

A novel DNA display strategy, based on a new puromycin modifier, has been developed. The 5′-end puromycin-tethered oligonucleotide was synthesized to hybridize with mRNA, so that it could attack the nascent polypeptides during in vitro translation. The DNA–peptide fusion molecule can tolerate more harsh and stringent selection conditions, therefore, this DNA display may become a useful tool for in vitro display technologies for the selection of peptide drug candidates.

Graphical abstract: DNA display for drug discovery

Supplementary files

Article information

Article type
Communication
Submitted
16 May 2013
Accepted
15 Jul 2013
First published
16 Jul 2013

RSC Adv., 2013,3, 16251-16254

DNA display for drug discovery

H. Chen, G. Chen, F. Du, Q. Fu, Y. Zhao and Z. Tang, RSC Adv., 2013, 3, 16251 DOI: 10.1039/C3RA42440E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements